A Comparative Effectiveness Study of Lorazepam or IVIg Versus no Treatment for Down Syndrome Regression Disorder
At the endpoint of 24 weeks, both IVIg and lorazepam were superior to no treatment for DSRD but IVIg was superior to lorazepam for all five outcomes. Between 12 and 24 weeks of treatment, IVIg showed greater improvement in all outcomes than did lorazepam, suggesting that at least a 24-week treatment course is necessary for maximum IVIg benefit.
Authors
- Eileen A. Quinn
- Robyn A. Filipink
- Ajay X. Thomas (ORCID: https://orcid.org/0000-0001-5249-3255)
- Jonathan Douglas Santoro (ORCID: https://orcid.org/0000-0002-8350-8234)
- Nidhiben Anadani
- Mellad Khoshnood (ORCID: https://orcid.org/0000-0003-2232-8341)
- Noemi Alice Spinazzi (ORCID: https://orcid.org/0000-0001-5009-7670)
- Lina Nguyen
- Lilia Kazerooni (ORCID: https://orcid.org/0009-0003-4147-5395)
- Panteha Hayati Rezvan
- Benjamin N. Vogel
- Melanie A. Manning
- Michael S. Rafii
- Cathy Franklin
- Saba Jafarpour
Institutions
- University of Southern California (US)
- Children's Hospital of Los Angeles (US)
- The University of Queensland (AU)
- University of California, San Francisco (US)
- Santa Barbara Cottage Hospital (US)
- Mater Research (AU)
- Children's Hospital of Pittsburgh (US)
- Texas Children's Hospital (US)
- University of Oklahoma (US)
- University of Toledo (US)
- Stanford University (US)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2026-03-08
- DOI
- https://doi.org/10.1007/s40120-026-00906-2
- Primary Topic
- Down syndrome and intellectual disability research
- Type
- article
- Field-Weighted Citation Impact
- 0.00